Dr. Lim Si Jing Joline

Dr Joline Lim is a medical oncologist at Mount Elizabeth Hospitals and Gleneagles Hospital, Singapore.

Her clinical and research focus is on female cancers, particularly breast oncology, new anti-cancer therapies, cancer prevention and survivorship.

Dr Lim is currently a visiting senior consultant at the National University Cancer Institute, Singapore.

She completed her medical oncology specialisation at the National University Hospital where she served as a senior consultant in the department of haematology-oncology. She pursued research training at Beth Israel Deaconess Medical Center/Brigham and Women’s Hospital, Harvard Medical School, USA. With a keen interest in new anti-tumour therapies including molecular targeted agents and immunotherapies, Dr Lim completed advanced training in drug development at The Royal Marsden Hospital, UK, on the National Medical Research Council’s (NMRC) training fellowship.

Her efforts in novel combination strategies in breast cancer led to her being awarded the Conquer Cancer Foundation of ASCO Merit Award, ESMO Travel Merit Award and Transitional Award from the NMRC. She has published in top-tiered journals in the oncology field. She has been practising medicine for more than 15 years.

An advocate that patients should not only live longer but also better, Dr Lim is active in improving survivorship care including scalp and limb cooling methodologies to reduce chemotherapy-induced toxicities. She is a lead investigator in studies for novel peripheral cryocompression devices to reduce chemotherapy induced peripheral neuropathy, a common and potentially debilitating side effect from chemotherapy.

Besides her clinical work, she is an assistant professor at Yong Loo Ling School of Medicine.

Preparation and Administration of Chemotherapy
Abdominal paracentesis
Lumbar Puncture

Turner, N., Saura, C., Aftimos, P., Van Den Tweel, E., Oesterholt, M., Koper, N., Colleoni, M., Kaczmarek, E., Punie, K., Song, X., Armstrong, A., Bianchi, G., Stradella, A., Ladoire, S., Lim, J. S. J., Quenel-Tueux, N., Tan, T. J., Escrivá-De-Romaní, S., O’Shaughnessy, J., . . . Klint, L. (2024). Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2–Positive advanced or metastatic breast cancer: an Open-Label, Randomized, Phase III trial (TULIP). Journal of Clinical Oncology.

Lim, J. S., Wong, A. L., Ow, S. G., Ngoi, N. Y., Chan, G. H., Ang, Y. L., Chong, W. Q., Lim, S. E., Lim, Y. W., Lee, M., Choo, J. R., Tan, H. L., Yong, W. P., Soo, R. A., Tan, D. S., Chee, C. E., Sundar, R., Yadav, K., Jain, S., . . . Lee, S. (2022). Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research, 28(11), 2248–2256.

Pascual, J., Lim, J. S. J., Macpherson, I. R., Armstrong, A. C., Ring, A., Okines, A. F. C., Cutts, R. J., Herrera-Abreu, M. T., Garcia-Murillas, I., Pearson, A., Hrebien, S., Gevensleben, H., Proszek, P. Z., Hubank, M., Hills, M., King, J., Parmar, M., Prout, T., Finneran, L., Malia, J., … Turner, N. C. (2021). Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discovery, 11(1), 92–107.

Yong, K. J., Gao, C., Lim, J. S., Yan, B., Yang, H., Dimitrov, T., Kawasaki, A., Ong, C. W., Wong, K., Lee, S., Ravikumar, S., Srivastava, S., Tian, X., Poon, R. T., Fan, S. T., Luk, J. M., Dan, Y. Y., Salto-Tellez, M., Chai, L., & Tenen, D. G. (2013). Oncofetal GeneSALL4in aggressive hepatocellular carcinoma. New England Journal of Medicine, 368(24), 2266–2276.